Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | KCNE1 | P15382 | 1/20 | 0.36 |
| ▸ | CCR1 | P32246 | 1/20 | 0.36 |
| ▸ | KCNQ1 | P51787 | 1/20 | 0.36 |
| ▸ | CALCA | P06881 | 2/20 | 0.35 |
| ▸ | RORC | P51449 | 5/20 | 0.33 |
| ▸ | NAMPT | P43490 | 1/20 | 0.33 |
| ▸ | ERCC1 | P07992 | 1/20 | 0.33 |
| ▸ | FEN1 | P39748 | 1/20 | 0.33 |
| ▸ | ERCC4 | Q92889 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 2/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | THRB | P10828 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3840946 | 0.92 | KCNH2 (0.40) | KCNH2CYP2C9KCNE1CCR1KCNQ1 | |
| SCHEMBL3836803 | 0.92 | KCNH2 (0.41) | KCNH2CYP2C9KCNE1CCR1KCNQ1 | |
| SCHEMBL3838390 | 0.89 | KCNH2 (0.43) | KCNH2CYP2C9KCNE1CCR1KCNQ1 | |
| SCHEMBL12778161 | 0.87 | PTGDR2 (0.38) | KCNH2CYP2C9CALCANAMPTKMT2A | |
| SCHEMBL3836233 | 0.87 | KCNH2 (0.38) | KCNH2CYP2C9KCNE1CCR1KCNQ1 | |
| SCHEMBL2080672 | 0.87 | KCNH2 (0.46) | KCNH2CYP2C9KCNE1CCR1KCNQ1 | |
| SCHEMBL4830816 | 0.86 | KCNH2 (0.42) | KCNH2CYP2C9KCNE1CCR1KCNQ1 | |
| SCHEMBL14064655 | 0.86 | KCNH2 (0.40) | KCNH2CYP2C9KCNE1CCR1KCNQ1 | |
| SCHEMBL4830889 | 0.85 | KCNH2 (0.40) | KCNH2CYP2C9KCNE1CCR1KCNQ1 | |
| SCHEMBL2079046 | 0.85 | KCNH2 (0.49) | KCNH2CYP2C9KCNE1CCR1KCNQ1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050256109-A1 | HIV integrase inhibitors: cyclic pyrimidinone compounds | BRISTOL-MYERS SQUIBB COMPANY | 2005-11-17 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050256109-A1 | HIV integrase inhibitors: cyclic pyrimidinone compounds | TYMP, TYMS, SAMHD1 | KCNH2 3435/4885CYP2C9 1079/4885KCNE1 4436/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.